AI & ChatGPT searches , social queries for SORAFENIB
Search references for SORAFENIB. Phrases containing SORAFENIB
See searches and references containing SORAFENIB!
Search references for SORAFENIB. Phrases containing SORAFENIB
See searches and references containing SORAFENIB!SORAFENIB
Cancer treatment medicine
Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma)
Sorafenib
Common type of liver cancer
months. The most common side effects of Sorafenib include a hand-foot skin reaction and diarrhea. Sorafenib is thought to work by blocking growth of
Hepatocellular_carcinoma
phase 3 randomized, open-label, clinical trial of Pexa-Vec plus sorafenib versus sorafenib is being conducted on patients with advanced hepatocellular carcinoma
Pexastimogene_devacirepvec
Medical condition
of liver cancer produced sorafenib, a targeted therapy drug that prevents cell proliferation and blood cell growth. Sorafenib obtained FDA approval for
Liver_cancer
Protein-coding gene in humans
conformations of the kinase domain as cancer therapeutic candidates. BAY43-9006 (Sorafenib, Nexavar) is a V600E mutant B-Raf and C-Raf inhibitor approved by the
BRAF_(gene)
Cancer medication
and various receptor tyrosine kinases. It is a deuterated derivative of sorafenib with improved pharmacokinetic properties. Keam SJ, Duggan S (November
Donafenib
Chemical compound
hepatocellular carcinoma for people who have been previously treated with sorafenib;[failed verification] and locally advanced or metastatic differentiated
Cabozantinib
Benign nerve-sheath tumor in the peripheral nervous system
Peginterferon alfa-2b is being studied to treat plexiform neurofibromas. Sorafenib is being studied for treatment of unresectable plexiform neurofibroma
Neurofibroma
American pharmaceutical company
partner at early investor, IVP. Co-developed and co-marketed with Bayer, sorafenib—sold under the trade name Nexavar—is a drug approved in the United States
Onyx_Pharmaceuticals
Class of pharmaceutical drugs
inhibited by sorafenib. Giving sorafenib in combination with rifampicin or inducers of CYP3A4 can decrease plasma concentration of sorafenib. CYP3A4 inhibitors
VEGFR-2_inhibitor
Medication
sorafenib to transition to tivozanib following progression disease but not those on the experimental arm using tivozanib to transition to sorafenib.
Tivozanib
Substance that inhibits the growth of new blood vessels
diastolic was reported in the first 24 hours after the first treatment with sorafenib, a VEGF pathway inhibitor.[non-primary source needed] Because these drugs
Angiogenesis_inhibitor
Cancer medication
DT, Dutcher J (March 2007). "Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma". Southern Medical
Sunitinib
Medication which blocks growth of blood vessels
molecules that inhibit the tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and pazopanib (some of these therapies target VEGF receptors
Anti-VEGF
Chemical compound
with advanced hepatocellular carcinoma who were previously treated with sorafenib. MetastaticCRC: After the CORRECT trial, two phase 3 trials (CONSIGN,
Regorafenib
Chemical compound
fipronil, fluazinam, penthiopyrad, picoxystrobin, fluridone, norflurazon, sorafenib, and triflurazin. The biological activity of trifluoromethyl compounds
Trifluoromethylation
Research hospital in Italy
Randomized, Open Label, Multicenter Phase 2 Study, to Evaluate the Efficacy of Sorafenib in Patients With Advanced Renal Cell Carcinoma After a Radical Resection
Casa Sollievo della Sofferenza
Casa_Sollievo_della_Sofferenza
Medication
C-kit and PDGFR (Avapritinib Axitinib Masitinib Pazopanib Ripretinib Sorafenib Sunitinib Toceranib) FLT3 (Lestaurtinib, Gilteritinib (AXL, ALK, LTK))
Elranatamab
Drug typically used in cancer treatment
treatment, with the most common toxicity being diarrhea. Imatinib, sunitinib, sorafenib, and pazopanib have been studied in the treatment of aggressive fibromatosis
Tyrosine_kinase_inhibitor
Medication
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Oclacitinib
SSRI antidepressant
"The selective serotonin reuptake inhibitors enhance the cytotoxicity of sorafenib in hepatocellular carcinoma cells". Anticancer Drugs. 32 (8): 793–801
Sertraline
German multinational pharmaceutical and biotechnology company
greater extent than some other classes of birth control pills. Nexavar (sorafenib) is a kinase inhibitor used in the treatment of liver cancer (hepatocellular
Bayer
Pharmaceutical compound
PHASE1 COMPLETED Clinical trial number NCT0149744 at ClinicalTrials.gov Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Advanced Kidney
Evofosfamide
Corticosteroid medication
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Dexamethasone
Chemical compound
Brivanib alaninate is a multitargeted tyrosine kinase inhibitor (as is sorafenib). Brivanib alaninate also inhibits VEGFR and fibroblast growth factor
Brivanib_alaninate
Abnormal yellowish skin colour caused by high level of bilirubin
with yellowing of the skin as a side effect: quinacrine, sunitinib, and sorafenib. Yellow discoloration of the skin can also rarely occur with hypercupremia
Jaundice
P38 mitogen-activated protein kinases
for clinical use, kinase inhibitors that also inhibit Raf kinases (e.g. Sorafenib) are successful antineoplastic agents against various types of cancer
Mitogen-activated protein kinase
Mitogen-activated_protein_kinase
Systematic naming of drugs
buparlisib -parib PARP inhibitor olaparib, veliparib -rafenib BRAF inhibitors sorafenib, vemurafenib -tinib Tyrosine-kinase inhibitors erlotinib, crizotinib -zomib
Drug_nomenclature
Medication and naturally occurring steroid hormone
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Testosterone_(medication)
Monoclonal anti-PD-L1 antibody
followed by bevacizumab 15 mg/kg IV on the same day, every 3 weeks, or sorafenib orally twice daily. In July 2020, it was approved in the United States
Atezolizumab
Rare form of cancer
therapy (IL-2, interferon), kinase inhibitors (temsirolimus, sunitinib, sorafenib, pazopanib) and anti-angiogenic therapies (bevacizumab). "Clear cell carcinoma"
Clear-cell_carcinoma
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
GDNF_family_of_ligands
Informal term for a drug that binds to many different molecular targets or receptors
Parkinson's disease. Examples of "promiscuous" cancer drugs include: sunitinib, sorafenib, vandetanib, and axitinib.[citation needed] In the field of drugs used
Dirty_drug
Chemical compound
showed significantly extended progression-free survival when compared to sorafenib. In December 2011, the Oncologic Drugs Advisory Committee (ODAC) voted
Axitinib
Pharmaceutical drug
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Belimumab
Tricyclic antidepressant
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Amitriptyline
Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone - Full Text View - ClinicalTrials.gov". Retrieved 2018-06-16
SillaJen
Protein found in humans
Assay, which is used to detect the FLT3 mutation in patients with AML. Sorafenib has been reported to show significant activity against Flt3-ITD positive
CD135
Monosaccharide sugar
Ramakrishna (2019-09-01). "Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment"
Galactose
American biotechnology company
treatment of hepatocellular carcinoma in adults previously treated with sorafenib". Ipsen.com. Retrieved 2026-07-28. "Institute for Clinical and Economic
Exelixis
Protein that stimulates red blood cell production
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Erythropoietin
Chemical compound
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Encorafenib
Protein found in humans
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Insulin-like_growth_factor_1
Chemical compound
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Tucatinib
Medication investigated as a treatment for progeria
potential with chemotherapeutics by enhancing sensitivity to agents like sorafenib, paclitaxel, and docetaxel, potentially overcoming drug resistance through
Lonafarnib
Chemical compound
In 2016, the FDA granted IND for clinical tests in combination with sorafenib for HCC. 4SC say "In several phase I and phase II trials, resminostat
Resminostat
Protein-coding gene in the species Homo sapiens
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
TRAF3
Primary male sex hormone
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Testosterone
Type of therapy
Because of this finding, erlotinib has replaced gefitinib in this setting. Sorafenib (Nexavar) Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib
Targeted_therapy
Using this method has contributed to the discovery of the drug Sorafenib (Nexavar). Sorafenib is used as medication to treat multiple types of cancers, including
High_throughput_biology
Medical condition
FLT3-ITD and the DEK-NUP214 protein are potential targets for treatment. Sorafenib is a kinase inhibitor used as a treatment for kidney and liver cancer
Acute myeloblastic leukemia with maturation
Acute_myeloblastic_leukemia_with_maturation
Reddening, swelling, numbness and skin peeling due to chemotherapy
Targeted cancer therapies, especially the tyrosine kinase inhibitors sorafenib and sunitinib, have also been associated with a high incidence of acral
Chemotherapy-induced acral erythema
Chemotherapy-induced_acral_erythema
Pharmaceutical drug classification
Capmatinib L01EP02 Tepotinib L01EP03 Savolitinib L01EX01 Sunitinib L01EX02 Sorafenib L01EX03 Pazopanib L01EX04 Vandetanib L01EX05 Regorafenib L01EX06 Masitinib
ATC_code_L01
Medical usage of the prasterone compound
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Prasterone
Enzyme that metabolizes substances by oxidation
teniposide, vinblastine, vincristine, vindesine, imatinib, irinotecan, sorafenib, sunitinib, vemurafenib, temsirolimus, anastrozole, gefitinib; azole antifungals:
CYP3A4
Form of kidney cancer
Sunitinib Cabozantinib Everolimus Ipilimumab Lenvatinib Pazopanib Bevacizumab Sorafenib Tivozanib Temsirolimus Interleukin-2 (IL-2) has produced "durable remissions"
Renal_cell_carcinoma
Pharmaceutical drug
fetoprotein (AFP) of > 400 ng/mL and have been previously treated with sorafenib. The approval was based on REACH-2 (NCT02435433), a multinational, randomized
Ramucirumab
Egyptian-American medical researcher
discovered a potent cancer therapeutic interaction between TRAIL and sorafenib. In 2013, his group reported a TRAIL-inducing compound TIC10 as a novel
Wafik_El-Deiry
Class of proteins produced by muscle
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Myokine
Cheilitis characterized by inflammation of one or both of the corners of the mouth
drug-induced xerostomia. Various examples include isotretinoin, indinavir, and sorafenib. Isotretinoin (Accutane), an analog of vitamin A, is a medication which
Angular_cheilitis
Protein found in humans
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Death_receptor_5
Protein-coding gene in the species Homo sapiens
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Granulocyte colony-stimulating factor receptor
Granulocyte_colony-stimulating_factor_receptor
Transport protein for insulin-like growth factor 1
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Insulin-like growth factor–binding protein
Insulin-like_growth_factor–binding_protein
Chemical compound
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Dehydroepiandrosterone
Chemical compound
thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib and for the treatment of people aged twelve years of
Selpercatinib
Malignancy originating in the thyroid gland
when it recurs after resection, or to relieve pain from bone metastasis. Sorafenib and lenvatinib are approved for advanced metastatic thyroid cancer. Numerous
Thyroid_cancer
Mammalian protein found in humans
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
CD30
Cancer of the myeloid line of blood cells
Multidisciplinary Digital Publishing Institute. Retrieved 6 June 2026. "Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome
Acute_myeloid_leukemia
Class of biochemical compounds
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Cucurbitacin
Chemical compound
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Motesanib
lung cancers 2006 – US FDA approves herceptin 2007 – US FDA approves sorafenib 2007 – US FDA approves camptothecin-analogue topotecan for chemotherapy
Timeline of cancer treatment development
Timeline_of_cancer_treatment_development
Protein-coding gene in the species Homo sapiens
trials have found that the first generation tyrosine kinase inhibitors sorafenib, sunitinib, midostaurin, lestaurtinib have shown some promise in treating
ETV6
Protein-coding gene in the species Homo sapiens
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
IFNA4
Medical condition
angiogenesis, blocking growth and suppressing spread of the tumor. Sunitinib, sorafenib, and axitinib are TKIs with anti-vascular endothelial growth factor (VEGF)
Papillary renal cell carcinoma
Papillary_renal_cell_carcinoma
Chemical compound
administration → significant tumor reduction, TKTL1↓. HCC (sorafenib-resistant): Combination with sorafenib reduces tumor burden, ROS↑, resensitization. CML
Oxythiamine
Monoclonal antibody
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Namilumab
Medical intervention
N, Furuichi Y, Imai Y (2013). "Hepatocellular carcinoma treated with sorafenib: Early detection of treatment response and major adverse events by contrast-enhanced
Medical_ultrasound
Type II cytokine receptor
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Interferon-lambda_receptor
Pharmaceutical drug
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Pertuzumab
Category of small signaling proteins
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Cytokine
Group of blood-based disorders
FIP1L1-PDGFRA. Second generation tyrosine kinase inhibitors, e.g. bosutinib, sorafenib, and nilotinib, show little success in treating T674I FIP1L-PDGFRA mutations
Clonal_hypereosinophilia
Pharmaceutical compound
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Epoetin_theta
Chemical compound
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
K252a
Greek-American pathologist
regeneration and sensitivity to sorafenib, highlighting that loss of LSP1 function increases sensitivity to sorafenib treatment and promotes hepatocellular
George_Michalopoulos
Protein-coding gene in the species Homo sapiens
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
IGFBP2
Chemical compound
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
HIOC
Mammalian protein found in Homo sapiens
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
FGF5
Proteoglycan; lubricant; gene
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Proteoglycan_4
Heterodimeric receptor
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Interferon-alpha/beta receptor
Interferon-alpha/beta_receptor
Protein found in humans
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Ephrin_B1
Protein-coding gene in humans
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
MST1R
Combination drug
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Pertuzumab/trastuzumab/hyaluronidase
Pertuzumab/trastuzumab/hyaluronidase
Medication to treat hair loss
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Ritlecitinib
Chemical compound, used as a medication to treat lung cancer
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Osimertinib
French biopharmaceutical company
(hepatocellular carcinoma) in adults previously treated with the medicine sorafenib, as well as in radioiodine-refractory differentiated thyroid cancer (RAI-R
Ipsen
Chemical compound
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Foretinib
Protein-coding gene in the species Homo sapiens
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
ADCYAP1R1
Medication
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Trastuzumab
Peptide hormone
Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1
Insulin
Medication
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib
Tofacitinib
SORAFENIB
SORAFENIB
SORAFENIB
SORAFENIB
SORAFENIB
SORAFENIB
SORAFENIB
SORAFENIB
SORAFENIB